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Abstract. 
Perivascular epithelioid cell tumors (PEComas) are mesenchymal tumors with a particular 
perivascular epithelioid cell differentiation. These tumors are extremely rare and represent a 
form of malignancy with certain characterizations. The TSC1/2 gene mutation can develop in 
both tuberous sclerosis complex (TSC)-related PEComa and sporadic cases. The mTORC1 
pathway activation is also found in these tumors. Currently, mTOR inhibitors have been used 
for the treatment of PEComas, and some reports have shown durable responses with the use of 
such mTOR inhibitors. We present a 71-year-old woman who had recurrent PEComa which 
was refractory to temsirolimus and everolimus. 
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病例報告  
以 mTOR 抑製劑治療無效的血管周圍上皮樣細胞腫瘤 
陳三奇 楊茜文 顏厥全 曾成槐 趙大中* 
台北榮民總醫院 內科部血液腫瘤科 
中文摘要 
  血管周圍上皮樣細胞腫瘤是由血管周圍上皮樣細胞所構成的間質腫瘤的統稱。這類
腫瘤非常少見，且有不同的惡性度。TSC1/2 基因的突變可以發生在與結節性硬化症相關
的或偶發性的血管周圍上皮樣細胞腫瘤。在這些腫瘤也發現有 mTORC1 路徑的活化，使
得 mTOR 抑制劑很合理的被嘗試在治療這類的腫瘤。一些報告顯示 mTOR 抑制劑對腫瘤
治療有持久的反應。我們在此報告一位 71 歲患有血管周圍上皮樣細胞腫瘤的女性，復發
後對於特癌適以及癌伏妥的治療無效。 
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INTRODUCTION 
Perivascular epithelioid cell tumors (PEComas) 
are rare tumors classified by the World Health Organ-
ization as “mesenchymal tumors composed of histo-
logically and immunohistochemically distinctive peri-
vascular epithelioid cells” [1]. The PEComa family 
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 includes angiomyolipoma (AML), LAM (lymphan-
gioleiomyomatosis) and PEComas which have not 
been otherwise specified (PEComas-NOS). AML pre-
sented as an asymptomatic renal lesion with vascular, 
muscle and adipocytic differentiation. LAM is caused 
by a proliferation disorder of the smooth muscle 
throughout the lung in premenopausal women. Both 
of the diseases are commonly seen in tubular sclerosis 
complex [2].  
The PEComa-NOS can develop at any age, and is 
female predominant. In one review, 40% of PEComa- 
NOS cases were of gynecologic origin; other origi-
nating sites included the colon, pancreas, retroperito-
neum, heart, adrenal gland, breast, eye, biliary tract, 
bone, urinary bladder, skull base, liver, skin and soft 
tissue [3]. Most PEComa-NOSs are benign, but some 
presented with malignant behavior involving invasion, 
local recurrence or distant metastasis. There are no 
optimal treatments for malignant PEComa besides 
tumor resection. Though the subset of PEComa-NOS 
is less associated with TSC, the disease activates the 
mTOR pathway as well. We presented a case of pelvic 
PEComa and shared the experience of treatment with 
mTOR inhibitors.  
   
CASE REPORT 
A 71-year-old woman presented with moderate 
abdominal pain 1 month in duration. She further re-
ported a sensation of fullness, poor appetite and con-
stipation. A subsequent physical examination revealed 
a distended abdomen with a palpable mass in the low-
er abdominal area. There were no stigmata of tuberous 
sclerosis complex on the skin. Additionally, the pa-
tient’s medical history included left temporal arach- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. (A) A 13 cm mass in the pelvic cavity was 
identified with peritoneal seeding. (B) CT 
image obtained after resection of pelvic 
tumors 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Gross feature: well demarcated with capsule 
formation, tan to black with foci of necrosis 
 
 
noid cyst status post shunt insertion, major depression 
and left ovarian cyst status post operation. The ab- 
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Figure 3. (A) Microscopic examination showed sheets of epithelioid cells with abundant clear to eosinophilic cy-
toplasm, vested with a prominent capillary vasculature. (B) The tumor cells were immuno-reactive for 
HMB-45. (C) The tumor cells were non-reactive for Melan A. (D) The tumor cells were non-reactive 
for S-100 
 
dominal CT revealed a 13 cm mass in the pelvic cavi-
ty with peritoneal seeding (Figure 1A). The tumor was 
heterogeneous with central necrosis. The CBC showed 
a WBC of 3800/cumm, Hb 10.3 g/dl, and platelets at 
198,000/cumm. Her biochemistry revealed LDH 645 
U/L and normal liver and renal function. The patient’s 
serum tumor marker showed CA125 was 282.0 U/ml 
(<35 U/ml) and CEA 1.59 ng/ml (<6 ng/ml). Soon 
thereafter, the patient underwent resection of the pel-
vic mass, retroperitoneal mass, part of the peritonea, 
total hysterectomy and bilateral salpingo-oophorectomy 
(Figure 1B).  
In gross, the patient’s tumor had invaded the ret-
roperitoneal cavity, the left pelvic wall, sigmoid colon 
and bladder wall (Figure 2). Microscopic examination 
showed a tumor composed of sheets of epithelioid 
cells with abundant clear to eosinophilic cytoplasm, 
vested with a prominent capillary vasculature (Figure 
3A). Marked nuclear pleomorphism, tumor necrosis 
and mitotic activity (2/10 high power field) were pre-
sent. Within the tumor, some hyalinized small vessels 
and large thick-walled vessels were identified. Intra-
cytoplasmic brown to black melanin pigment was 
identified with Fontana-Masson stain. The tumor cells 
were immuno-reactive for HMB-45 (Figure 3B), 
while non-reactive for Melan A (Figure 3C), S-100  
A B
C D
130 S. C. Chen et al./JCRP 1(2014) 128-133
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. (A) Pelvic recurrence 4 months after surgery. 
(B) CT image showed stable disease 2 
months after temsiolimus treatment. (C) In-
terstitial pneumonitis developed 6 weeks 
after everolimus treatment 
 
 
protein (Figure 3D), muscle specific actin (HHF-35), 
desmin, CD10, and RCC. The pathology report con-
firmed the diagnosis of perivascular epithelioid cell 
tumor (PEComa). 
After the surgery, the patient did not receive adju-
vant therapy. She remained disease- free for 4 months 
until a follow-up CT scan showed pelvic recurrence 
(Figure 4A). Temsiolimus was initially given 25 mg 
i.v. weekly, and thereafter a tumor evaluation carried 
out 2 months later revealed her disease had stabilized 
(Figure 4B). However, the CA125 level increased 
rapidly from 282 U/ml to 659 U/ml. After discussing 
these changed circumstances with the patient, her 
treatment was changed to oral everolimus 5 mg twice 
daily. However, interstitial pneumonitis occurred after 
6 weeks use of everolimus (Figure 4C). The everoli-
mus regimen was suspended, and then resumed at a 
lower dose with 5 mg daily three weeks later. There-
after, a new tumor evaluation carried out 16 weeks 
later revealed disease progression with new lung le-
sions. Due to poor performance status, we withheld 
further curative or sustaining medication and provided 
supportive care. One month later, the patient died of 
disease progression. 
 
DISCUSSION 
The natural course of PEComa can be variable, 
ranging from benign to aggressive behavior including 
metastasis. Folpe et al. proposed criteria for the classi-
fication of PEComas in 2005 using these features: 1) 
tumor size >5 cm, 2) infiltrative growth pattern, 3) 
high nuclear grade, 4) necrosis and 5) mitotic activity 
>1/50 HPF [4]. These authors describe PEComa as 
“benign” if none of the criteria are met, “uncertain 
malignant potential” if the tumor is larger than 5 cm or 
has high nuclear grade, and “malignant” if the tumor 
fulfills more than 2 worrisome features. Our case sat-
isfied the criteria for “malignant”, which was compat-
ible with the disease’s clinical course. However, the 
role and efficacy of using this classification for guid-
ing treatment options in the future remains uncertain.  
Tumors in the PEComa family usually develop 
sporadically. Among this group of diseases, LAM and 
AML are often seen in patients with tuberous sclerosis 
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 complex (TSC). TSC is caused by the mutation of 
TSC1 or TSC2 tumor suppression genes. Studies have 
found the frequent loss of heterozygosity of the TSC2 
gene on 16p12 in both TSC-related PEComa and spo-
radic cases[5]. Thus, the TSC1/TSC2 protein complex 
lost its ability to inhibit the activation of mTORC1 
through the Rheb GTPase [2]. The upregulation of 
mTORC1 pathway resulted in cell survival, prolifera-
tion and protein synthesis.  
Kenereson et al. [6] described an activated 
mTORC1 pathway with increased levels of phos-
pho-p70S6K detected by immunohistochemical assay 
in all 15 PEComas. They also found that with the re-
duction of AKT phosphorylation, there was a noted 
loss of TSC1/2 function in 14 of 15 PEComas. Pan et 
al. [7] also reported similar results with elevated 
phospho-p70S6K, and the absence of AKT phophory-
lation in 12 PEComas. No strong evidence was shown 
which supported whether the effect of mTOR inhibitor 
correlates with the status of mTORC1 activation. Only 
one study showed that detection of phospho-p70S6K 
can potentially predict mTOR inhibitor response.  
Bissler et al. [8] reported using sirolimus to treat 
25 patients with AML or LAM. In their study, the typ-
ical tumor regressed during sirolimus treatment for 1 
year but rebounded after sirolimus use was halted. In 
addition, there are several case reports presented 
where mTOR inhibitors were used to treat PEComas. 
Wagner et al. presented 3 PEComas that responded to 
sirolimus treatment, though only one patient experi-
enced a response duration greater than 1 year [9]. 
Dickson et al. reported using mTOR inhibitors with a 
5/11 (45%) complete response, 1/11 (9%) partial re-
sponse and 5/11 (45%) progression disease [10]. The 
treatment was tolerable and the longest response dura-
tion was up to 2 years. In that study, no significantly 
different effects between the use of sirolimus, temsiro-
limus and everolimus were observed. However, our 
patient who was subsequently treated with temsiroli-
mus and everolimus derived only marginal benefit 
from them. The mechanism of drug resistance to 
mTOR inhibitors remains unknown. In addition, there 
is still no established factor that predicts mTOR inhib-
itors response. 
The mTOR inhibitors have shown promising re-
sponse in about half of the malignant PEComas, and 
have become an important treatment option for this 
rare disease. Further studies are needed to define the 
optimal treatment strategy. 
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